All Stories

  1. PolyP and APC fight a RAGEing battle
  2. Plasmodium falciparum picks (on) EPCR
  3. Neurotoxicity of the anticoagulant-selective E149A-activated protein C variant after focal ischemic stroke in mice
  4. Novel mechanisms for activated protein C cytoprotective activities involving noncanonical activation of protease-activated receptor 3
  5. Mechanisms of anticoagulant and cytoprotective actions of the protein C pathway
  6. Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46
  7. Protein C anticoagulant and cytoprotective pathways
  8. EPCR encryption induces cellular APC resistance
  9. A knockout for knockin
  10. Platelet Factor 4 Inhibits Thrombomodulin-dependent Activation of Thrombin-activatable Fibrinolysis Inhibitor (TAFI) by Thrombin
  11. Activated protein C
  12. ACTIVATED PROTEIN C
  13. The cytoprotective protein C pathway
  14. The promise of protein C
  15. Protein C anticoagulant activity in relation to anti-inflammatory and anti-apoptotic activities
  16. Thrombin activatable fibrinolysis inhibitor (TAFI)—How does thrombin regulate fibrinolysis?
  17. Activated protein C variants with normal cytoprotective but reduced anticoagulant activity
  18. Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor
  19. Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets
  20. Thrombin Activatable Fibrinolysis Inhibitor (TAFI) at the Interface between Coagulation and Fibrinolysis
  21. Thrombin-Activatable Fibrinolysis Inhibitor Deficiency in Cirrhosis Is Not Associated With Increased Plasma Fibrinolysis
  22. Thrombin-Activatable Fibrinolysis Inhibitor (TAFI, Plasma Procarboxypeptidase B, Procarboxypeptidase R, Procarboxypeptidase U)
  23. Reduced activity of TAFI (thrombin‐activatable fibrinolysis inhibitor) in acute promyelocytic leukaemia